Royal Bank of Canada
NAVB

Royal Bank of Canada’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Royal Bank of Canada’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,000
Closed -$106K – 6282
2013
Q3 		$106K Buy
+2,000
New +$117K ﹤0.01% 4444

Other funds holding NAVB

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Royal Bank of Canada's NAVB Position: Q2 2023 in Review

Royal Bank of Canada sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2023, closing a stake of 1 share.

Royal Bank of Canada first reported a position in NAVB in Q2 2013 and held it in 27 quarters. The position peaked at $149K in Q3 2013. 23 funds tracked by Wall St. Rank hold NAVB as of Q2 2023.

  • Royal Bank of Canada reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
  • Royal Bank of Canada sold 1 Navidea Biopharmaceuticals Inc. share in Q2 2023.
  • Royal Bank of Canada first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 27 quarters.
  • Royal Bank of Canada's Navidea Biopharmaceuticals Inc. position peaked at $149K in Q3 2013.
  • 23 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2023.

Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.